Study shows prostate cancer treatment may cause bone decay
The report, which was published in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, followed 26 men with prostate cancer who began ADT over a 12-month period.
At several points during the research, measurements were taken for sex steroid levels, bone turnover markers and bone mineral density.
"We used a new technology that allows us to assess bone microarchitecture and we found ADT is associated with structural decay of corticol (hard outer shell) and trabecular (spongy inner mesh) bone," said Emma Hamilton and Mathis Grossmann, lead authors of the study. "This technology may be a useful test in predicting fractures in patients, but further research is needed in identifying individuals at greatest fracture risk as well as optimal therapeutic strategies."
Prostate cancer relies upon male hormones for its growth and ADT is a common treatment because it suppresses or blocks the production or action of male sex hormones. This is the first study to examine changes in bone structure during ADT.
Last updated on 10/13/2010
First published on 10/08/2010